

Applicants: Michael R. Hale et al.  
Application No.: 10/626,356

### REMARKS

#### The Response

##### *The Restriction Requirement*

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

- I. Claims 1-13 and 18-22, drawn to variously classified products; and
- II. Claims 23 and 27-41, drawn to methods of use for the products of Group

I.

Applicants elect Group I without traverse. Applicants note that claims 23 and 27-41 are drawn to methods of using the compounds recited in Group I. Thus, applicants request that the claims of Group II be rejoined with those of Group I when those claims are indicated as allowable.

The Examiner has further required an election of a single compound, including an exact definition of each substitution on the base molecule wherein a single member at each substituent group or moiety is selected.

Applicants elect compound IIA-141. In accordance with the Examiner's requirement, applicants specify that for compound IIA-141, Ht is pyrrol-3-yl, A is N, B is O, R<sup>1</sup> is R<sup>5</sup> and R<sup>5</sup> is H, R<sup>3</sup> is R and R is H, T is a valence bond, R<sup>2</sup> is phenyl substituted with two R<sup>8</sup>, wherein both R<sup>8</sup> substituents are halogen (one is chloro and one is fluoro), Q is -C(O)- and R<sup>4</sup> is N(R<sup>6</sup>)<sub>2</sub>, wherein the two R<sup>6</sup> are R<sup>5</sup>, which in turn are both aliphatic groups that are taken with the N to which they are attached to form a heterocyclic ring.

Applicants reserve their right to traverse the restriction requirement until the examiner has provide a genus in the first Office Action.

This election is made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or in other applications claiming benefit herefrom.


RECEIVED  
CENTRAL FAX CENTER  
AUG 01 2005

Applicants: Michael R. Hale et al.  
Application No.: 10/626,356

Conclusion

Applicants allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,



Karen E. Brown  
Reg. No. 43,866  
Attorney/Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483